132 related articles for article (PubMed ID: 23004574)
1. Insights from Pim1 structure for anti-cancer drug design.
Ogawa N; Yuki H; Tanaka A
Expert Opin Drug Discov; 2012 Dec; 7(12):1177-92. PubMed ID: 23004574
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
3. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
4. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
5. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
[TBL] [Abstract][Full Text] [Related]
6. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
Holder SL; Abdulkadir SA
Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
[TBL] [Abstract][Full Text] [Related]
7. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
[TBL] [Abstract][Full Text] [Related]
8. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
[TBL] [Abstract][Full Text] [Related]
10. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
[TBL] [Abstract][Full Text] [Related]
11. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors.
Olla S; Manetti F; Crespan E; Maga G; Angelucci A; Schenone S; Bologna M; Botta M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1512-6. PubMed ID: 19179076
[TBL] [Abstract][Full Text] [Related]
12. A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide.
Tsuganezawa K; Watanabe H; Parker L; Yuki H; Taruya S; Nakagawa Y; Kamei D; Mori M; Ogawa N; Tomabechi Y; Handa N; Honma T; Yokoyama S; Kojima H; Okabe T; Nagano T; Tanaka A
J Mol Biol; 2012 Mar; 417(3):240-52. PubMed ID: 22306408
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
Holder S; Zemskova M; Zhang C; Tabrizizad M; Bremer R; Neidigh JW; Lilly MB
Mol Cancer Ther; 2007 Jan; 6(1):163-72. PubMed ID: 17218638
[TBL] [Abstract][Full Text] [Related]
14. Pim kinase inhibitors: a survey of the patent literature.
Morwick T
Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
[TBL] [Abstract][Full Text] [Related]
15. Identification of quinones as novel PIM1 kinase inhibitors.
Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.
Kumar A; Mandiyan V; Suzuki Y; Zhang C; Rice J; Tsai J; Artis DR; Ibrahim P; Bremer R
J Mol Biol; 2005 Apr; 348(1):183-93. PubMed ID: 15808862
[TBL] [Abstract][Full Text] [Related]
18. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase.
Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214
[TBL] [Abstract][Full Text] [Related]
19. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
